Trial Profile

A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin in Children With Growth Hormone Deficiency

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2025 Results assessing efficacy and safety published in the European Journal of Endocrinology
21 Mar 2024 Results of subanalysis evaluating the efficacy and tolerability of somapacitan in Japanese children with GHD after 104 weeks of treatment and after switch from daily, published in the Clinical Endocrinology
08 Dec 2023 Results investigating response prediction using pre-treatment transcriptome in children with GH deficiency (GHD) treated with once-weekly somapacitan, published in the Journal of Clinical Endocrinology and Metabolism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com